Brief: Fate Therapeutics Announces Positive Interim Clinical Data From FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

Fate Therapeutics

19/08/2021 22:46

Aug 19 (Reuters) - Fate Therapeutics Inc  FATE.O :
    * FATE THERAPEUTICS ANNOUNCES POSITIVE INTERIM CLINICAL DATA
FROM
ITS FT596 AND FT516 OFF-THE-SHELF, IPSC-DERIVED NK CELL PROGRAMS
FOR B-CELL LYMPHOMA
    * FATE THERAPEUTICS INC - 8 OF 11 PATIENTS IN FT516
MULTI-DOSE
ESCALATION COHORTS 2 AND 3 ACHIEVED OBJECTIVE RESPONSE
    * FATE THERAPEUTICS INC - 10 OF 14 PATIENTS IN FT596
SINGLE-DOSE
ESCALATION COHORTS 2 AND 3 ACHIEVED OBJECTIVE RESPONSE
    * FATE THERAPEUTICS INC - FT596 AND FT516 TREATMENT REGIMENS
WERE
WELL-TOLERATED
    * FATE THERAPEUTICS INC - NO DOSE-LIMITING TOXICITIES, AND
NO
ADVERSE EVENTS OF ANY GRADE OF ICANS OR GVHD, WERE OBSERVED
    * FATE THERAPEUTICS INC - TWO LOW-GRADE ADVERSE EVENTS OF
CRS WERE
REPORTED IN FT596 SINGLE-DOSE ESCALATION COHORTS 1 AND 2

Source text for Eikon:  ID:nGNX5LLgGz 
Further company coverage:  FATE.O